Advanced-Stage Prostate Cancer Patients Experience 20-Year Survival Rates With Surgery

	Tweet

Long-term survival rates for patients with advanced prostate cancer suggest they can be good candidates for surgery, Mayo Clinic researchers have found. Their study found a 20-year survival rate for 80 percent of patients diagnosed with cancer that has potentially spread beyond the prostate, known as cT3 prostate cancer, and treated with radical prostatectomy, or surgery to remove the prostate gland. Previously, patients found to have cT3 prostate cancer were offered radiation or hormone treatment, but not radical prostatectomy.

The researchers presented their findings during the American Urological Association Annual Meeting in Washington.

“We are doing a much better job of identifying and expanding candidates for surgery, which results in better, longer outcomes for so many of our patients,” says R. Jeffrey Karnes, M.D., of Mayo Clinic’s Department of Urology. “We have confirmed that patients diagnosed with locally advanced prostate cancer can enjoy a long, cancer-free interval.”

The 80 percent survival rate for cT3 diagnoses at 20 years compares to 90 percent for cT2, or cancer confined to the prostate. This long-term follow-up of patients who underwent surgery between 1987 and 1997 is an important advance in understanding the quality outcomes for cT3 patients. The study sample included patients diagnosed and operated on between 1987 and 1997. Ongoing research will examine contemporary data.

Other study investigators include Christopher Mitchell, M.D., Eric Umbreit, M.D., Rachel Carlson and Laureano Rangel, all of Mayo Clinic.

About Mayo Clinic
Mayo Clinic is a nonprofit worldwide leader in medical care, research and education for people from all walks of life.

###

Source: Mayo Clinic

RELATED STORIES:
Insight: New doubts about prostate-cancer vaccine Provenge   Delay OK before radiation for prostate cancer   Laser may reduce prostate surgery’s sexual side effects   Urine test improves prostate diagnosis   PSA value at 2 years post-treatment can predict long-term survival in prostate cancer patients   Fewer complications, better outcomes with robot-assisted prostate cancer surgery   Vaccine Injection Targeted in Building a Better ‘Bull’s-Eye’ to Fight Prostate Cancer   Abbott says access to prostate cancer drug widened   Testosterone Replacement in Older Men Does Not Increase Risk of Prostate Cancer   Prostate cancer patients disease free after 5 years likely to be disease free after 10 years   Scientists identify prostate cancer stem cells among low-PSA cells   Prostate cancer may respond to more hormone therapy   Study examines the use of a novel suprapubic catheter in suprapubic prostatectomy   Shorter radiation course as effective as standard therapy for prostate cancer recurrence   Exercise helps sex life after prostate radiation   Trimodal approach to prostate cancer promising   Herbal extract may treat prostate cancer   Low-grade prostate cancer may not require aggressive treatment   Older men may not need prostate cancer screening   Prostate Cancer Risk Among Users of Finasteride and Alpha-Blockers   Genetic mutations associated with increased PSA and prostate cancer   MicroRNA suppresses prostate cancer stem cells and metastasis

Comments

[ + Post Your Own ]

Now you're in the public comment zone. What follows is not Armenian Medical Network's stuff; it comes from other people and we don't vouch for it. A reminder: By using this Web site you agree to accept our Terms of Service. Click here to read the Rules of Engagement.

There are no comments for this entry yet. [ + Comment here + ]